CWIAX
Price
$82.59
Change
+$0.54 (+0.66%)
Updated
Jun 2 closing price
Net Assets
151.89B
VMVFX
Price
$17.10
Change
+$0.01 (+0.06%)
Updated
Jun 2 closing price
Net Assets
1.99B
Interact to see
Advertisement

CWIAX vs VMVFX

Header iconCWIAX vs VMVFX Comparison
Open Charts CWIAX vs VMVFXBanner chart's image
CWIAX vs VMVFX Comparison Chart in %
View a ticker or compare two or three
VS
CWIAX vs. VMVFX commentary
Jun 03, 2026

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is CWIAX is a Buy and VMVFX is a Hold.

Interact to see
Advertisement
FUNDAMENTALS
Fundamentals
CWIAX has more cash in the bank: 152B vs. VMVFX (1.99B). VMVFX pays higher dividends than CWIAX: VMVFX (2.15) vs CWIAX (1.33). CWIAX was incepted earlier than VMVFX: CWIAX (24 years) vs VMVFX (12 years). CWIAX (0.75) is less costly to investors than VMVFX (0.21). CWIAX (44.00) and VMVFX (43.00) have comparable annual turnover. CWIAX has a lower initial minimum investment than VMVFX: CWIAX (250) vs VMVFX (3000). CWIAX annual gain was more profitable for investors over the last year : 22.44 vs. VMVFX (2.90). CWIAX return over 5 years is better than : 38.19 vs. VMVFX (19.52).
CWIAXVMVFXCWIAX / VMVFX
Total Expense Ratio0.750.21357%
Annual Report Gross Expense Ratio0.750.21357%
Fund Existence24 years12 years-
Gain YTD15.6528.370187%
Front Load4%N/A-
Min. Initial Investment25030008%
Min. Initial Investment IRAN/AN/A-
Net Assets152B1.99B7,623%
Annual Yield % from dividends1.332.1562%
Returns for 1 year22.442.90775%
Returns for 3 years54.6525.69213%
Returns for 5 years38.1919.52196%
Returns for 10 years122.6351.97236%
View a ticker or compare two or three
Interact to see
Advertisement
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
CSHAX12.600.20
+1.61%
NYLI Cushing® MLP Premier Class A
JCPRX25.76N/A
N/A
JPMorgan US Large Cap Core Plus R5
OIEIX26.19N/A
N/A
JPMorgan Equity Income A
RYBOX65.18N/A
N/A
Rydex Biotechnology A
PSKCX23.33N/A
N/A
Virtus KAR Mid-Cap Growth C